CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
propranolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000493
NCT00000493Phase 3Completed
CompareCT.gov

Multicenter Investigation of Limitation of Infarct Size (MILIS)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Jul 12, 2016

In Brief

A Phase 3 clinical trial evaluating propranolol and hyaluronidase for Cardiovascular Diseases and 4 related conditions. Completed.

Detailed Summary

To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Infarction, Myocardial Ischemia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartSep 1, 1977
Study CompletionDec 1, 1985
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

propranololdrug

hyaluronidasedrug